The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent

医学 经皮冠状动脉介入治疗 传统PCI 支架 临床终点 心肌梗塞 内科学 靶病变 心脏病学 药物洗脱支架 急性冠脉综合征 外科 随机对照试验
作者
Matteo Nardin,Carlo Andrea Pivato,Davide Cao,Samantha Sartori,Zhongjie Zhang,Birgit Vogel,Johny Nicolas,Mauro Chiarito,Hanbo Qiu,Jaya Chandrasekhar,Alessandro Spirito,Alexandre Abizaid,Evald Høj Christiansen,Antonio Colombo,Robbert J. de Winter,Michael Haude,Lars Jakobsen,Lisette Okkels Jensen,Mitchell W. Krucoff,Ulf Landmesser,Shigeru Saïto,Harry Suryapranata,Giuseppe De Luca,George Dangas,Roxana Mehran
出处
期刊:International Journal of Cardiology [Elsevier BV]
卷期号:370: 149-155 被引量:3
标识
DOI:10.1016/j.ijcard.2022.10.133
摘要

COMBO (OrbusNeich Medical, Hong Kong) is a dual-therapy coronary stent featuring sirolimus as antiproliferative drug and an anti-CD34+ antibody coating to attract endothelial progenitor cells favoring rapid stent re-endothelization. The Mega COMBO collaboration aimed to evaluate the performance of the COMBO stent in a large contemporary cohort of patients undergoing percutaneous coronary intervention (PCI).Patient-level data of subjects undergoing PCI with the COMBO stent from the REMEDEE-Trial, REMEDEE-OCT, HARMONEE, REDUCE, SORT OUT X, REMEDEE-Registry and MASCOT studies were pooled together. The primary endpoint was 1-year target lesion failure (TLF), a composite of cardiovascular death, target vessel myocardial infarction (TV-MI) or clinically driven target lesion revascularization (CD-TLR). Secondary outcomes were the individual components of the primary endpoint and stent thrombosis (ST). Endpoints were evaluated against performance goals based on the EAPCI (the European Association of Percutaneous Coronary Intervention) recommendations for new drug-eluting stents.A total of 6753 patients (mean age 63.7 ± 11.4 years, 23% women) were included. At 1-year follow-up, TLF occurred in 303 (4.6%) patients. The rates of cardiovascular death, TV-MI, and CD-TLR were 1.3%, 1.8%, and 2.5%, respectively. The rate of definite/probable ST was 0.73%, early ST (<1 month) was 0.48%, while late ST (1-12 months) was 0.26%. The performance goals were met for all of the evaluated endpoints.This large patient-level pooled analysis provides a comprehensive outline of the performance of the dual-therapy COMBO stent. The low rates of primary and secondary endpoints suggest that this stent technology may be a good alternative to other contemporary drug eluting coronary stent platforms.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
如花_HuaHua发布了新的文献求助10
2秒前
2秒前
我们完成签到,获得积分10
3秒前
3秒前
yiyi完成签到 ,获得积分10
3秒前
烟花应助Leeie03采纳,获得10
5秒前
6秒前
7秒前
8秒前
8秒前
伯赏觅翠完成签到 ,获得积分10
8秒前
8秒前
wzc完成签到,获得积分10
8秒前
双楠应助朱马大采纳,获得10
9秒前
9秒前
hyf发布了新的文献求助10
10秒前
幸福大白发布了新的文献求助10
11秒前
11秒前
zyw发布了新的文献求助10
11秒前
五六七发布了新的文献求助10
13秒前
闾丘剑封发布了新的文献求助10
13秒前
可爱的函函应助小晓采纳,获得10
16秒前
Owen应助SciEngineerX采纳,获得10
16秒前
幸福大白发布了新的文献求助30
17秒前
内向寒云完成签到,获得积分10
19秒前
CipherSage应助DC采纳,获得10
19秒前
淡然的花卷完成签到,获得积分10
20秒前
22秒前
无语的不言完成签到,获得积分20
23秒前
23秒前
慕青应助lzx采纳,获得10
24秒前
24秒前
24秒前
Orange应助欧耶采纳,获得10
25秒前
25秒前
25秒前
yyyyyyy完成签到,获得积分10
27秒前
SciEngineerX发布了新的文献求助10
28秒前
木木完成签到,获得积分10
28秒前
啧啧啧发布了新的文献求助10
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989450
求助须知:如何正确求助?哪些是违规求助? 3531621
关于积分的说明 11254315
捐赠科研通 3270207
什么是DOI,文献DOI怎么找? 1804928
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809176